Clinical Trial Update: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations [Phase 1]

View source ↗

Summary

Phase 1 study of LY3410738 in patients with IDH1/IDH2-mutant advanced solid tumors, including cholangiocarcinoma, chondrosarcoma, and glioma; the study is activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Chondrosarcoma
• Glioma

Drugs mentioned

• LY3410738 (LY3410738)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Cholangiocarcinoma, Chondrosarcoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING